Therapies / Research / Clinical / Cancer / Drugs / Drug / DNA / Pharmaceuticals / Pharmaceutical / Boston / Boston blog main / Boston top stories / National blog main / cancer / Cancer Drug / cancer therapy / Cystic Fibrosis / David Altshuler / Development / DNA damage / DNA damage and repair / Drug Development / exome / Gilead Sciences / Hepatitis C / immune-oncology / Immuno-oncology / Incivek / Ivacaftor / Jeff Leiden / Jefferies / Kalydeco / Life Science / Life Sciences / Lungs / Merck / mucus / out-licensing / Phase 1 / phase 2 / protein kinase inhibitor / R&D / rare disorders / research / sofosbuvir / Sovaldi / telaprevir / Therapy / Vertex / Vertex Pharmaceuticals / VX-970

Vertex Deals Cancer Drugs to Merck for $230M, Staying True to Plan

Posted on: Jan 11, 2017   |   Posted by: Biotech Mag

Vertex Deals Cancer Drugs to Merck for $230M, Staying True to Plan

Vertex Pharmaceuticals is unloading a group of ancillary research programs in its portfolio, announcing today it will out-license the potential cancer treatments to Darmstadt...

Continue reading ...